Table 2 Clinical features of 16 treated patients presenting with MHHs.
Cases | No. of skin lesions | Sex | Age at diagnosis | Treatment for IHs | Follow-up/outcome |
|---|---|---|---|---|---|
1 | None | Female | 3.5 m | Oral prednisone | 61 m |
2 | None | Female | 3.0 m | Oral propranolol | 40 m |
3 | 1 | Female | 5 m | Oral propranolol | 26 m |
4 | 4 | Male | 3 m | Intralesional triamcinolone injection | 60 m |
5 | 6 | Male | 4.5 m | Oral prednisone and vincristine | Died from CHF |
6 | 7 | Female | 1.8 m | Oral prednisone | 84 m |
7 | 8 | Female | 2 m | Intralesional triamcinolone injection | 48 m |
8 | 11 | Female | 2.2 m | Oral propranolol | 30 m |
9 | 16 | Male | 3.0 m | Oral prednisone, embolization | Died from respiratory distress and coagulopathy |
10 | 21 | Male | 5.0 | Oral prednisone | 60 m |
11 | 30–100 | Female | 1.0 m | Oral propranolol | 52 m |
12 | 30–100 | Male | 1.2 m | Oral prednisone | 72 m |
13 | 30–100 | Female | 1.8 m | Oral prednisone | 80 m |
14 | Innumerable | Female | 2 m | Oral prednisone | 90 m |
15 | Innumerable | Male | 1. 5 m | Oral propranolol | 32 m |
16 | Innumerable | Female | 2.1 m | Oral propranolol | 38 m |
